ID: ALA5208227

Max Phase: Preclinical

Molecular Formula: C33H35N3O6S

Molecular Weight: 601.73

Representations

Canonical SMILES:  COc1ccc2c3c1O[C@H]1[C@H](N(C)C(=O)/C=C/c4ccoc4)CC=C4[C@@H](C2)N(S(=O)(=O)c2ccccc2N(C)C)CC[C@]431

Standard InChI:  InChI=1S/C33H35N3O6S/c1-34(2)24-7-5-6-8-28(24)43(38,39)36-17-16-33-23-11-12-25(35(3)29(37)14-9-21-15-18-41-20-21)32(33)42-31-27(40-4)13-10-22(30(31)33)19-26(23)36/h5-11,13-15,18,20,25-26,32H,12,16-17,19H2,1-4H3/b14-9+/t25-,26-,32+,33+/m1/s1

Standard InChI Key:  MBETVHLFGXAETJ-NSCYIRBMSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 601.73

Molecular Weight (Monoisotopic): 601.2247

AlogP: 4.24

#Rotatable Bonds: 7

Polar Surface Area: 92.53

Molecular Species: NEUTRAL

HBA: 7

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 0.14

CX LogP: 3.60

CX LogD: 3.60

Aromatic Rings: 3

Heavy Atoms: 43

QED Weighted: 0.30

Np Likeness Score: 0.51

References

1. Katoh K, Kutsumura N, Yamamoto N, Nagumo Y, Saitoh T, Ishikawa Y, Irukayama-Tomobe Y, Tanimura R, Yanagisawa M, Nagase H..  (2022)  Essential structure of orexin 1 receptor antagonist YNT-707: Conversion of the 16-cyclopropylmethyl group to the 16-sulfonamide group in d-nor-nalfurafine derivatives.,  59  [PMID:35041942] [10.1016/j.bmcl.2022.128550]

Source

Source(1):

• Scientific Literature